Celebrating Editorial Board Members of Cancer Drug Resistance Journal Named Among the “World’s Top 2% Scientists 2024”
On September 16, 2024, Elsevier, a leading global academic publisher, and Stanford University jointly released the 7th edition of the “World’s Top 2% Scientists 2024” list. We are excited to congratulate 25 Editorial Board members of the Cancer Drug Resistance (CDR) journal for being included in this prestigious ranking.
Godefridus J. Peters
Gdanski Uniwersytet Medyczny, Poland
Yehuda G. Assaraf
Technion - Israel Institute of Technology, Israel
Paola Perego
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Zhe Sheng Chen
St. John's University, USA
Robert W. Robey
National Institutes of Health (NIH), USA
Sanjay Gupta
CASE School of Medicine, USA
Gautam Sethi
National University of Singapore, Singapore
Roger Phillips
University of Huddersfield, UK
Raphael Pollock
The Ohio State University Wexner Medical Center, USA
Maria R. Baer
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, USA
Aamir Ahmad
Hamad Medical Corporation, Qatar
Paul Dent
Virginia Commonwealth University, USA
William H. Gmeiner
Wake Forest University School of Medicine, USA
Erik A.C. Wiemer
Erasmus MC, Netherlands
William C. Cho
Queen Elizabeth Hospital, Hong Kong, China
Dominique Heymann
CNRS Centre National de la Recherche Scientifique, France
Rakesh K. Srivastava
VA Medical Center, USA
David A. Gewirtz
Virginia Commonwealth University, USA
Thomas Hutson
Texas Oncology, USA
Paolo Ettore Porporato
Università degli Studi di Torino, Italy
Dean G. Tang
Roswell Park Cancer Institute, USA
Ahmad Safa
Indiana University School of Medicine, USA
John D. Schuetz
St. Jude Children's Research Hospital, USA
Michael M. Gottesman
National Institutes of Health (NIH), USA
Marco Falasca
Università di Parma, Italy
(Note: The names are listed in no particular order. For any corrections or updates regarding the statistics, please feel free to reach out to the editorial department. )
The “World’s Top 2% Scientists 2024” list is compiled using data from the Scopus database and takes into account six key factors: total citations (distinguishing between self-citations and external citations), Hirsch H-index, Schreiber Hm-index adjusted for co-authorship, and contributions as sole, first, or lead author. From a pool of nearly 7 million scientists globally, the top 2% are selected across 22 fields and 174 subfields. This prestigious recognition highlights the exceptional contributions of CDR's Editorial Board members to academia and underscores the journal’s significant impact on cancer drug resistance research.
Editor: Belinda Zhao
Language Editor: Catherine Yang
Production Editor: Yan Zhang
Respectfully submitted by the Editorial Office of Cancer Drug Resistance.
